Difference between revisions of "Team:UParis BME/Results"

Line 76: Line 76:
 
                                         <b>A plasmid to produce any toehold switch candidates</b>
 
                                         <b>A plasmid to produce any toehold switch candidates</b>
 
                                     </h2>
 
                                     </h2>
                                     <p class="textContent">Pierre Nioche kindly provided us with a GFP tagged protein and pET24d(+) plasmid. The first step was to  build a pET24d(+)_GFP plasmid by assembling GFP and pET-24d(+) using molecular cloning with restriction enzymes. (Figure 1)
+
                                     <p class="textContent">Pierre Nioche kindly provided us with a GFP tagged protein and pET24d(+) plasmid. The first step was to  build a pET24d(+)_GFP plasmid by assembling GFP and pET-24d(+) using molecular cloning with restriction enzymes. (<b>Figure 1</b>)
 
</p>
 
</p>
  
Line 84: Line 84:
 
</figure>
 
</figure>
  
<p class="textContent">We first amplified the GFP fragment from the GFP tagged protein via polymerase chain reaction (PCR) to get a higher quantity of DNA for molecular cloning. At each step, samples were analyzed by gel electrophoresis to validate the step. Figure 2 shows that after PCR we have obtained a unique fragment (one band in the red box) that is slightly below the 800bp band from the NEB 100bp ladder. This fragment corresponds to the expected EGFP fragment with the two restriction sites EcorI and XhoI at its extreme sides, which is 738bp long.</p>
+
<p class="textContent">We first amplified the GFP fragment from the GFP tagged protein via polymerase chain reaction (PCR) to get a higher quantity of DNA for molecular cloning. At each step, samples were analyzed by gel electrophoresis to validate the step. <b>Figure 2</b> shows that after PCR we have obtained a unique fragment (one band in the red box) that is slightly below the 800bp band from the NEB 100bp ladder. This fragment corresponds to the expected EGFP fragment with the two restriction sites EcorI and XhoI at its extreme sides, which is 738bp long.</p>
  
 
<figure>
 
<figure>
Line 92: Line 92:
 
</figure>
 
</figure>
  
<p class="textContent">We next aimed to integrate this PCR amplified GFP fragment into the plasmid pET-24d(+). GFP fragments and pET-24d(+) are thus digested using the restriction enzymes EcorI and XhoI overnight. The efficiency of digestion was checked by electrophoresis. Figure 3 shows that pET-24d(+) was successfully digested: the well loaded with the digest samples exhibit a unique band corresponding to linearized DNA (open and digested plasmid), compared to the well loaded with an undigested plasmid that shows two bands for the two forms of a plasmid.</p>
+
<p class="textContent">We next aimed to integrate this PCR amplified GFP fragment into the plasmid pET-24d(+). GFP fragments and pET-24d(+) are thus digested using the restriction enzymes EcorI and XhoI overnight. The efficiency of digestion was checked by electrophoresis. <b>Figure 3<b> shows that pET-24d(+) was successfully digested: the well loaded with the digest samples exhibit a unique band corresponding to linearized DNA (open and digested plasmid), compared to the well loaded with an undigested plasmid that shows two bands for the two forms of a plasmid.</p>
  
 
<figure>
 
<figure>
Line 100: Line 100:
 
</figure>
 
</figure>
  
<p class="textContent">The GFP fragment was then integrated into the linearized pET-24d(+) plasmid  using 10 minute ligation protocol with the NEB T4 ligase. To amplify the plasmid, Bl21(DE3) <i>E. coli</i> were transformed with the ligated product using heat shock protocol. Since pET-24d(+) plasmid contains the kanamycin resistance gene,  bacteria were cultured overnight on kanamycin LB (Luria Broth) to select the <i>E. coli</i> who have integrated the plasmid. From this transformation, we selected 8 clones that we're able to grow on our kanamycin media and form colonies. After DNA extraction from these 8 clones, we have made a PCR  to amplify the GFP fragment to verify the integration of the GFP fragment into the plasmid. Figure 4 shows that PCR has amplified a fragment of more than 500pb from DNA of the colonies 2, 4, 5,6 and not from other colonies. This fragment presented the expected size of GFP, suggesting the success of the ligation. To confirm the good construction of our plasmid, we sent it to sequencing (Eurofins Genomics) and clones 2,4,6 were positive with our new construction (Figure 4).</p>
+
<p class="textContent">The GFP fragment was then integrated into the linearized pET-24d(+) plasmid  using 10 minute ligation protocol with the NEB T4 ligase. To amplify the plasmid, Bl21(DE3) <i>E. coli</i> were transformed with the ligated product using heat shock protocol. Since pET-24d(+) plasmid contains the kanamycin resistance gene,  bacteria were cultured overnight on kanamycin LB (Luria Broth) to select the <i>E. coli</i> who have integrated the plasmid. From this transformation, we selected 8 clones that we're able to grow on our kanamycin media and form colonies. After DNA extraction from these 8 clones, we have made a PCR  to amplify the GFP fragment to verify the integration of the GFP fragment into the plasmid. <b>Figure 4</b> shows that PCR has amplified a fragment of more than 500pb from DNA of the colonies 2, 4, 5,6 and not from other colonies. This fragment presented the expected size of GFP, suggesting the success of the ligation. To confirm the good construction of our plasmid, we sent it to sequencing (Eurofins Genomics) and clones 2,4,6 were positive with our new construction (<b>Figure 4</b>).</p>
  
 
<figure>
 
<figure>
Line 115: Line 115:
 
</figure>
 
</figure>
  
<p class="textContent">We named this newly engineered plasmid pET-24d(+)_GFP and it contains the part <a href="http://parts.igem.org/Part:BBa_K3878000">BBa_K3878000</a> (EGFP followed by a T7terminator); its vector map is detailed on Figure 5. This plasmid pET-24d(+)_GFP is the receiving vector to insert the variable part of the toehold switch. The plasmid keeps the T7 promoter and most of the restriction site. One point that can be addressed is the disparition of the EcorI site.</p>
+
<p class="textContent">We named this newly engineered plasmid pET-24d(+)_GFP and it contains the part <a href="http://parts.igem.org/Part:BBa_K3878000">BBa_K3878000</a> (EGFP followed by a T7terminator); its vector map is detailed on <b>Figure 5</b>. This plasmid pET-24d(+)_GFP is the receiving vector to insert the variable part of the toehold switch. The plasmid keeps the T7 promoter and most of the restriction site. One point that can be addressed is the disparition of the EcorI site.</p>
  
 
</div>
 
</div>
Line 125: Line 125:
 
                                         <b>Production of complete toehold switches</b>  
 
                                         <b>Production of complete toehold switches</b>  
 
                                     </h2>
 
                                     </h2>
                                     <p class="textContent">We tried several methods (detailed in /<a href="https://2021.igem.org/Team:UParis_BME/Wetlab">wetlab</a>) to get the toehold switch directly fully synthesized or the variable part of the toehold switch (Figure 6) ready to be assembled into a plasmid that already encodes the repressed gene, GFP.</p>
+
                                     <p class="textContent">We tried several methods (detailed in /<a href="https://2021.igem.org/Team:UParis_BME/Wetlab">wetlab</a>) to get the toehold switch directly fully synthesized or the variable part of the toehold switch (<b>Figure 6</b>) ready to be assembled into a plasmid that already encodes the repressed gene, GFP.</p>
  
 
<figure>
 
<figure>
Line 137: Line 137:
 
<p class="textContent">SOE PCR is the first technique we tried to synthesize one of the full Toehold Switch sequences with. Three sets of backward primers were designed and ordered to enable the step-by-step assembly. The size of the primers depends on the set but is on average from 40 to 70 bps.</p>
 
<p class="textContent">SOE PCR is the first technique we tried to synthesize one of the full Toehold Switch sequences with. Three sets of backward primers were designed and ordered to enable the step-by-step assembly. The size of the primers depends on the set but is on average from 40 to 70 bps.</p>
  
<p class="textContent">SOE with the first set of primers: The PCR1 performed with the first backward primer leads to a successful elongation of the starting sequence (EGFP) with the right expected size (Figure 7A). Indeed, electrophoresis gel migration reveals the bands corresponding to the PCR1 product being placed slightly higher than the band corresponding to the GFP migration (Figure 7A). The same is true for the PCR2 performed using the product from the PCR1 with the second backward primer together (Figure 7B). The PCR2 product still migrates less compared to the PCR1 and is then of higher molecular weight (Figure 7B). However, the PCR3 performed with the PCR2 product together with the third backward primer did not complete the Toehold Switch synthesis. The PCR3 product is of very low quantity, and moreover, it seems to be placed lower than the PCR2 product, which means that the sequence has not been elongated… To solve the problem we reproduced the three PCRs several times, but the PCR3 always leads to confusing results. We then decide to redesign the primers to solve the problem.</p>
+
<p class="textContent">SOE with the first set of primers: The PCR1 performed with the first backward primer leads to a successful elongation of the starting sequence (EGFP) with the right expected size (<b>Figure 7A</b>). Indeed, electrophoresis gel migration reveals the bands corresponding to the PCR1 product being placed slightly higher than the band corresponding to the GFP migration (<b>Figure 7A</b>). The same is true for the PCR2 performed using the product from the PCR1 with the second backward primer together (<b>Figure 7B</b>). The PCR2 product still migrates less compared to the PCR1 and is then of higher molecular weight (<b>Figure 7B</b>). However, the PCR3 performed with the PCR2 product together with the third backward primer did not complete the Toehold Switch synthesis. The PCR3 product is of very low quantity, and moreover, it seems to be placed lower than the PCR2 product, which means that the sequence has not been elongated… To solve the problem we reproduced the three PCRs several times, but the PCR3 always leads to confusing results. We then decide to redesign the primers to solve the problem.</p>
  
<p class="textContent">SOE with the second and third sets of primers: Second and third sets of primers were ordered and delivered. However, only the first two PCRs (PCR1 and PCR2) have been ever successful. The new primers used have not changed the results - after each PCR we were obtaining again something similar to the data represented in Figure 7C. We decided to abandon the strategy after several weeks of attempts.</p>  
+
<p class="textContent">SOE with the second and third sets of primers: Second and third sets of primers were ordered and delivered. However, only the first two PCRs (PCR1 and PCR2) have been ever successful. The new primers used have not changed the results - after each PCR we were obtaining again something similar to the data represented in <b>Figure 7C</b>. We decided to abandon the strategy after several weeks of attempts.</p>  
  
 
<figure>
 
<figure>
Line 157: Line 157:
  
  
<p class="textContent">The synthesized fragments, the variable part of the toehold switch targeting miR-141-5p, are received into plasmids from IDT and amplified with 10-BETA <i>E. coli</i> bacteria transformation. Plasmids with the variable part of the toehold switch are then successfully digested overnight using BamHI and BglII restriction enzymes. Figure 8 shows a unique band slightly smaller than 300pb, corresponding to the purified and digested fragment (between 260 to 290bp depending on the candidate).</p>
+
<p class="textContent">The synthesized fragments, the variable part of the toehold switch targeting miR-141-5p, are received into plasmids from IDT and amplified with 10-BETA <i>E. coli</i> bacteria transformation. Plasmids with the variable part of the toehold switch are then successfully digested overnight using BamHI and BglII restriction enzymes. <b>Figure 8</b> shows a unique band slightly smaller than 300pb, corresponding to the purified and digested fragment (between 260 to 290bp depending on the candidate).</p>
  
 
<figure>
 
<figure>
Line 165: Line 165:
 
</figure>
 
</figure>
  
<p class="textContent">The assembly of the variable part of the toehold switch into the plasmid pET-24d(+)_GFP was performed as previously but did not work as shown after sequencing of the plasmids with Eurofins Genomics (Figure 9). <br>
+
<p class="textContent">The assembly of the variable part of the toehold switch into the plasmid pET-24d(+)_GFP was performed as previously but did not work as shown after sequencing of the plasmids with Eurofins Genomics (<b>Figure 9</b>). <br>
 
Hypotheses on what went wrong:  We obtained a very low amount (~40 ng/μL) of plasmid and insert after the purification step, too low a concentration of both components significantly decreased our chance to get the good assembly product. In addition, BglII and BamHI generate the same sticky ends, meaning that the plasmid can close itself easily. We should have used a higher concentration of plasmids and inserts and better optimized our strategy to use other restriction enzymes that do not generate the same overhangs.</p>
 
Hypotheses on what went wrong:  We obtained a very low amount (~40 ng/μL) of plasmid and insert after the purification step, too low a concentration of both components significantly decreased our chance to get the good assembly product. In addition, BglII and BamHI generate the same sticky ends, meaning that the plasmid can close itself easily. We should have used a higher concentration of plasmids and inserts and better optimized our strategy to use other restriction enzymes that do not generate the same overhangs.</p>
  
Line 177: Line 177:
  
 
<p class="textContent">In parallel with the restriction enzyme method, we worked on another method using the NEB® Golden Gate Assembly Kit (BsaI-HF®v2). With the help of Manish Kushwaha, we designed the fragments coding for the variable part of the toehold switches targeting miR-21-5p preceded by T7 promoter. iGEM Evry kindly gave us the BBa_K3453101 as a plasmid for the golden gate assembly. The variable parts of the toehold switch are synthesized by IDT and received into a plasmid. We successfully amplified the fragment via PCR to get a high quantity of the fragments (between 100 and 200 ng/μl). <br>  
 
<p class="textContent">In parallel with the restriction enzyme method, we worked on another method using the NEB® Golden Gate Assembly Kit (BsaI-HF®v2). With the help of Manish Kushwaha, we designed the fragments coding for the variable part of the toehold switches targeting miR-21-5p preceded by T7 promoter. iGEM Evry kindly gave us the BBa_K3453101 as a plasmid for the golden gate assembly. The variable parts of the toehold switch are synthesized by IDT and received into a plasmid. We successfully amplified the fragment via PCR to get a high quantity of the fragments (between 100 and 200 ng/μl). <br>  
The amplified fragment was inserted into the BBa_K3453101 plasmid using NEB® Golden Gate Assembly Kit (BsaI-HF®v2). <i>E.coli</i> was transformed with the golden gate product. Since receiving plasmid contains the Tetracycline resistance gene, bacteria were cultured overnight on kanamycin LB (Luria Broth) to select the <i>E.coli</i> who have integrated the plasmid. We obtained 200 colonies per candidate. To confirm the success of the ligation, we performed a PCR amplification on the variable part of the toehold switch fragments. Figure 10 shows a similar band for each candidate, even for the negative control. We concluded that our construction is not a success and that none of the plasmids contains the variable part of the toehold switch. In addition, we sequenced some plasmids to the sequencing, and the results confirmed the non-assembly of the construct. None of them had the fragment cloned into the plasmid, as indicated in the gel run with PCR amplified fragment front.</p>
+
The amplified fragment was inserted into the BBa_K3453101 plasmid using NEB® Golden Gate Assembly Kit (BsaI-HF®v2). <i>E.coli</i> was transformed with the golden gate product. Since receiving plasmid contains the Tetracycline resistance gene, bacteria were cultured overnight on kanamycin LB (Luria Broth) to select the <i>E.coli</i> who have integrated the plasmid. We obtained 200 colonies per candidate. To confirm the success of the ligation, we performed a PCR amplification on the variable part of the toehold switch fragments. <b>Figure 10</b> shows a similar band for each candidate, even for the negative control. We concluded that our construction is not a success and that none of the plasmids contains the variable part of the toehold switch. In addition, we sequenced some plasmids to the sequencing, and the results confirmed the non-assembly of the construct. None of them had the fragment cloned into the plasmid, as indicated in the gel run with PCR amplified fragment front.</p>
  
  
Line 203: Line 203:
 
                                     </h2>
 
                                     </h2>
 
                                     <p class="textContent">In this part of the project, we aimed to verify that MCF-7 and HeLa cell lines are expressing abnormal quantities of exosomal miRNAs. These cell lines have been selected because they are well-characterized cancer cells, for human breast cancer cells and human cervical cancer, respectively (see our <a href="https://2021.igem.org/Team:UParis_BME/Wetlab">wetlab</a> section for more details)<sup>5</sup>.   
 
                                     <p class="textContent">In this part of the project, we aimed to verify that MCF-7 and HeLa cell lines are expressing abnormal quantities of exosomal miRNAs. These cell lines have been selected because they are well-characterized cancer cells, for human breast cancer cells and human cervical cancer, respectively (see our <a href="https://2021.igem.org/Team:UParis_BME/Wetlab">wetlab</a> section for more details)<sup>5</sup>.   
MCF-7 and HeLa cells were grown separately at a 70% of confluence as we can see in Figure 11.  
+
MCF-7 and HeLa cells were grown separately at a 70% of confluence as we can see in <b>Figure 11</b>.  
 
</p>
 
</p>
  
Line 219: Line 219:
  
 
<table>
 
<table>
   <caption>Table 1: protein concentrations in the samples of MCF-7, HeLa cells culture respectively after exosome extraction.</caption>
+
   <caption><b>Table 1: protein concentrations in the samples of MCF-7, HeLa cells culture respectively after exosome extraction.</b></caption>
 
   <tr>
 
   <tr>
 
     <th>n°</th>
 
     <th>n°</th>
Line 244: Line 244:
 
<p class="textContent">BCA results show protein concentration between 350 and 660 µg/mL, as described in Table 1. These concentrations are decent, leading to the assumption that we had vesicles. </p>
 
<p class="textContent">BCA results show protein concentration between 350 and 660 µg/mL, as described in Table 1. These concentrations are decent, leading to the assumption that we had vesicles. </p>
 
   
 
   
<p class="textContent">A western blot has been conducted to confirm the presence of exosomes in the vesicle extract, using CD9+ and CD63+ as surface markers and Calnexin as a negative control (non-exosomal protein). As shown on Figure 12, we observed a band for the CD63+ markers for the extracts from HeLa cells but not from MCF-7 cells. The negative control was The negative control Calnexin was expressed. Calnexin is an abundant 90kDA chaperone protein that resides in the membrane of the endoplasmic reticulum, and is not supposed to be expressed in exosomes. Calnexin was detected in samples from MCF-7 cells (A and B), meaning that it may not be pure exosomes. None of the vesicle extracts exhibit CD9+. This result is not that surprising because CD9 expression on exosomes vary with the cell type and the physiological conditions<sup>6-7</sup>. CD63+ was detected but not Calnexin for the sample from HeLa cells, we concluded that the vesicle extract from HeLa cells contained exosomes.</p>
+
<p class="textContent">A western blot has been conducted to confirm the presence of exosomes in the vesicle extract, using CD9+ and CD63+ as surface markers and Calnexin as a negative control (non-exosomal protein). As shown on <b>Figure 12</b>, we observed a band for the CD63+ markers for the extracts from HeLa cells but not from MCF-7 cells. The negative control was The negative control Calnexin was expressed. Calnexin is an abundant 90kDA chaperone protein that resides in the membrane of the endoplasmic reticulum, and is not supposed to be expressed in exosomes. Calnexin was detected in samples from MCF-7 cells (A and B), meaning that it may not be pure exosomes. None of the vesicle extracts exhibit CD9+. This result is not that surprising because CD9 expression on exosomes vary with the cell type and the physiological conditions<sup>6-7</sup>. CD63+ was detected but not Calnexin for the sample from HeLa cells, we concluded that the vesicle extract from HeLa cells contained exosomes.</p>
  
  
Line 260: Line 260:
 
<p class="textContent">Comparison of the variation of Cq using U6 primers, specific miRNA primers (targeting miR-34a, miR-141-5p and miR-21-5p), and between water and cDNA sample was done. H2O was added in place of cDNA sample as control value.  
 
<p class="textContent">Comparison of the variation of Cq using U6 primers, specific miRNA primers (targeting miR-34a, miR-141-5p and miR-21-5p), and between water and cDNA sample was done. H2O was added in place of cDNA sample as control value.  
 
We analyzed the difference between H2O and sample Cq, which is the number of cycles necessary to extract fluorescence from the noise of the qRT-PCR. Low Cq means high RNA quantity. U6 was the positive control of the well functionning of the qRT-PCR reaction. H2O Cq was higher than our cDNA Cq meaning that no errors have been done following the protocol. The Cq measured for miR-34a for the cDNA sample is equal to the Cq for the water. This indicates that miRNA-34a was not present in the exosomes extracted from HeLa cells, which was expected as this miRNA selected as a negative control for assessing miR-21-5p and miR-141-5p presence in cancer derived exosomes.
 
We analyzed the difference between H2O and sample Cq, which is the number of cycles necessary to extract fluorescence from the noise of the qRT-PCR. Low Cq means high RNA quantity. U6 was the positive control of the well functionning of the qRT-PCR reaction. H2O Cq was higher than our cDNA Cq meaning that no errors have been done following the protocol. The Cq measured for miR-34a for the cDNA sample is equal to the Cq for the water. This indicates that miRNA-34a was not present in the exosomes extracted from HeLa cells, which was expected as this miRNA selected as a negative control for assessing miR-21-5p and miR-141-5p presence in cancer derived exosomes.
The Cq measured for the miR-141-5p and miR-21-5p are lower in the cDNA sample than in the water (table 2), meaning that these miRNAs were contained within exosomes from the HeLa cells.</p>
+
The Cq measured for the miR-141-5p and miR-21-5p are lower in the cDNA sample than in the water (<b>table 2</b>), meaning that these miRNAs were contained within exosomes from the HeLa cells.</p>
 
   
 
   
 
<table>
 
<table>
 
     <caption>
 
     <caption>
     Table 2: Final results of qRT-PCR with mean Cq from each miRNA
+
     <b>Table 2: Final results of qRT-PCR with mean Cq from each miRNA.</b>
 
     We calculate the mean Cq of the triplicate of each miRNA with their primers in order to compare them with their respective blank.
 
     We calculate the mean Cq of the triplicate of each miRNA with their primers in order to compare them with their respective blank.
 
     </caption>
 
     </caption>

Revision as of 17:19, 21 October 2021